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AbstrACt
Objectives To elicit key factors influencing physicians’ 
decision to prescribe statins.
Design A qualitative study using a phenomenological 
approach within a pragmatism interpretive framework. 
A combination of purposive and snowball sampling was 
used to recruit physicians. Data were collected through 
face- to- face, semistructured interviews with physicians 
working in primary healthcare facilities in a capital of a 
province in Indonesia. We recorded and verbatim transcribed 
the interviews. Coding was done independently by two 
researchers and data were analysed using phenomenological 
data analyses. Key factors influencing physicians’ decision 
to prescribe statins were classified into factors at the 
microlevels, mesolevels and macrolevels according to the 
structural model by Scoggins et al.
Participants and setting Physicians working in primary 
healthcare facilities in a capital of a province in Indonesia.
results Ten physicians were included in the study. Key 
factors at the microlevel were that physicians knew 
guidelines in general, but there was uncertainty how to take 
into account the level of total cholesterol in combination 
with other cardiovascular risk factors such as diabetes and 
hypertension. At the macrolevel, the new National Health 
Insurance System (NHIS) that appeared to facilitate the 
prescription of statins though more clinical information 
should be integrated in the system’s platform to support 
appropriate prescribing.
Conclusions The findings indicate lack of awareness of 
specific details in current guideline recommendations. 
Appropriate prescribing of statins should be enhanced 
using the new NHIS.
IntrODuCtIOn
The use of statins has been endorsed by local 
and various international guidelines1–6 to 
prevent cardiovascular (CV) disease (CVD)- 
related events or death in individuals without 
history of previous CVD (primary prevention) 
or with established CVD (secondary preven-
tion).7–9 But many studies demonstrate under-
prescribing, and in some cases overprescribing 
of this drug class. Underprescribing of statins 
is especially an issue in primary prevention, 
for example, in the groups with moderate- to- 
very high risk of CVD in the European general 
population and in an outpatient setting in 
the USA.10–13 One small study (n=243 cases) 
with medical records data taken from three 
private hospitals in Jakarta, the capital city of 
the Republic of Indonesia, a lower middle- 
income country (LMIC), suggested patients 
might not be properly treated with statins. 
But underprescribing or overprescribing was 
not clearly defined, because data required to 
determine the appropriateness to prescribe 
statins are not routinely measured or well 
documented.14 15 Another study in ambulatory 
patients with diabetes with established CVD in 
Surabaya revealed the phenomenon of under-
prescribing with 43% of eligible patients not 
receiving statins.16 Studies investigating the 
consequences of underprescribing and over-
prescribing of statins are scarce. Nevertheless, 
one case study in a UK population with a ≥20% 
of 10- year risk of developing CVD, indicating 
the use of statins for primary prevention of 
strengths and limitations of this study
 ► This is the first study to gain insights from physicians 
on key factors influencing their decision in prescrib-
ing statins in a lower middle- income country setting.
 ► Face- to- face interviews by an interviewer who was 
known to physicians made it possible to gain more 
trustworthy information.
 ► Follow- up interviews, member checking process, 
independent coders, discussion with several re-
searchers to reach consensus and the use of a the-
oretical framework improved the credibility of the 
results.
 ► Despite code saturation was appropriately reached 
with a small sample size, a larger sample size 
is needed to obtain meaning saturation to pro-
vide a deeper understanding of the investigated 
phenomenon.
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Figure 1 Healthcare delivery system in Indonesia, figure 
was modified from Claramita et al.34 Puskesmas is a public 
primary health centre. Posyandu is a service organised by 
volunteers (Kader) to deliver health programme for vulnerable 
groups, especially mother and children, locally. Posyandu is 
supervised by Puskesmas.52
CVD, illustrates that underprescribing will substantially 
reduce quality- adjusted life years gained over a 9- year period 
(2006–2014) and overprescribing will certainly increase 
the cost burden of prescription between £80 million and 
£117 million annually without certainty whether the benefit 
of prevented CVD events outweighs the adverse drug 
reaction.17
Factors influencing physicians’ prescribing behaviour, 
regardless of the medication being prescribed, have been 
investigated since 1950s. Physicians’ personal and profes-
sional characteristics, pharmaceutical marketing strategies 
(direct- to- physician or direct- to- consumer marketing), 
drug information sources, drug characteristics, drug price 
and patients’ characteristics have been identified as factors 
influencing physicians’ prescribing behaviour, although 
there is inconsistency over the relative importance of each 
factor.18–24 More importantly, the majority of studies in this 
field have been conducted in high- income Western coun-
tries with a different culture, healthcare and health insur-
ance systems compared with LMICs.
In order to reach universal health coverage (UHC) in 
2019, the Government of Indonesia launched a new manda-
tory National Health Insurance System (NHIS) programme 
(Jaminan Kesehatan Nasional- Kartu Indonesia Sehat (JKN- KIS)) 
run by the Indonesian Social Security Agency for Health 
(Badan Pengelola Jaminan Sosial, BPJS Kesehatan) in 2014.25–27 
The system facilitates more patients to go to the primary 
healthcare facilities first instead of directly visiting specialists 
in the secondary facilities.25 28 Moreover, more medicines, 
listed in the 2014 revised edition of the National Formulary, 
are insured by the government to improve access to medi-
cations for patients.25 29 30 Based on the National Formulary, 
two types of statins are insured (pravastatin and simvastatin). 
An estimation of the total CV risk score, which is necessary 
to guide statin prescribing for primary prevention of CVD, 
is not mentioned.29 30 This policy is different compared with 
the new clinical guideline for patients with dyslipidaemia 
issued by the Indonesian Heart Association (IHA) which 
adapted guidelines issued by the European Society of Cardi-
ology and the European Atherosclerosis Society.2 31 In these 
guidelines, statins should be prescribed according to both 
the level of low- density lipoprotein cholesterol (LDL- c) and 
the total CV risk score, especially in patients with unknown 
or no history of CVD. Thus, this situation may create confu-
sion for physicians in prescribing statins and increase the 
risk of underprescribing or overprescribing of statins. In 
the current qualitative study, we aimed to understand the 
key factors influencing physicians to prescribe statins, espe-
cially in the primary healthcare facilities in an LMIC.
MethODs
study design and framework
This was a qualitative study using a phenomenological 
approach within a pragmatism interpretive framework. 
The pragmatism framework focuses on the phenomenon 
being investigated (key factors influencing physicians in 
prescribing statins) and the question inquired regarding 
this phenomenon. This framework allowed choosing the 
method that worked best in the field to answer the research 
question.32 We used the Standards for Reporting Qualita-
tive Research checklist when writing our report.33
study context and setting
As briefly introduced earlier, the Government of Indo-
nesia set a new NHIS conducted by BPJS Kesehatan, namely 
JKN- KIS, in 2014. In this system, Indonesia’s Ministry of 
Health also enforced the already existing platforms such 
as the National Formulary and the e- Catalogue to support 
cost- effective medicine and medical supply procurement 
throughout the country. The National Formulary lists medi-
cines reimbursed by BPJS. The e- Catalogue is a national elec-
tronic platform required to be used by healthcare facilities 
for procuring medicines. The e- Catalogue lists medicines 
with their prices and selected pharmaceutical companies as 
supplier. Unless the medicines which are needed are not 
listed in the e- Catalogue, it is mandatory for all healthcare 
facilities to purchase medicines from this platform.25 26
Indonesia’s primary healthcare is delivered by public and 
private primary healthcare facilities. Public primary health-
care facilities consist of primary health centres (PHCs or 
puskesmas) and their supporting networks (pustu, puskel, 
polindes, poskesdes) owned and organised by District or 
City Health Offices. Private primary healthcare facilities 
consist of individual practice general practitioners (GPs), 
midwives, and nurses; and private clinics. As a part of new 
NHIS program in 2014, the national referral system to 
access these facilities was also established. Figure 1 pres-
ents an overall picture of the healthcare delivery system in 
Indonesia.34
Participants
We viewed the topic of our study was sensitive in nature.35 36 
Prescribing activity in Indonesia is an authority of regis-
tered physicians governed by regulations37 38 and ethical 
codes.39 40 There might be issues which would not be frankly 
expressed due to its sensitivity. Thus, we selected a city, a 
capital of a province in Indonesia, where our study had 
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box 1 Interview guide
Questions
Main question
 ► Which factors do you consider when prescribing statins to the pa-
tient ?
Probing question (not necessarily being asked, depends on answers 
from the main question)
 ► Which therapeutic guideline did you usually use in prescribing 
statins ?
 ► How do you assess a total cardiovascular risk factor ?
 ► Which type of statins do you often prescribe ?
 ► Which statin dose and duration of use you prescribe ?
 ► How about the relation to pharmaceutical company promotion/ad-
vertising ?
 ► Does the regulation in the practice setting limit the decision of ther-
apy ?
 ► Have you ever found patients complaining about the cost of statins ?
 ► Are you having difficulties in arranging time for a consultation with 
the patient because there are many queues ?
 ► Does an insurance system such as the new national health insur-
ance programme limit you to prescribe statins to patients who need 
it ?
been welcomed and approved by the local physician associ-
ation of the city. We gathered information from physicians 
working at primary care health facilities in this city. The 
province was quite small with an area around 6000 ha. The 
city is the most populous city in the province with around 
900 000 inhabitants in 2017, about 21.5% of the province’s 
population. Indonesian regulation allows physicians to 
conduct their practice at a maximum of three healthcare 
facilities (public or private, primary or secondary level).38 
The views of the physicians included in our study reflect 
their practice to care for patients with and without CVD 
with possible indications for primary and secondary preven-
tion of CVD.
We obtained the list of physicians’ names registered as 
member of the physician association of the city, but up- to- 
date physicians’ personal contact details were not available. 
Therefore, we purposively selected physicians who worked 
at the primary healthcare facilities in the capital city who 
were known to a member of the research team (SP) in a 
personal (friendship) or professional (acquaintance) 
manner, and consented to participate in the study. Partic-
ipating physicians were then asked for contact details of 
potential other participants (snowball sampling).
Data collection
Baseline characteristics of the participants were collected by 
interview (age, practice experience, educational period). 
Initially, an interview guide was developed by SI and SP 
based on general key factors in prescribing found in the 
literature (see box 1).18 A semistructured face- to- face inter-
view was conducted with each participant by SP between July 
2015 and January 2016. To obtain the key factors consid-
ered by physicians in prescribing statins, SP only asked the 
main question at first. The probing questions were asked 
after physicians answered the first question in an explan-
atory way. All interviews were audio recorded using a tape 
recorder. The interviewer also took some field notes. The 
result from the initial interview of each participant was 
preanalysed directly by SI and SP to confirm whether it had 
covered the aim of the study and to determine if a follow- up 
interview with the same participant was needed. Data collec-
tion was discontinued when code saturation was reached as 
described by Hennink et al.41
Data analysis
The recorded interviews were listened to repeatedly and 
transcribed verbatim whenever possible. The field notes 
were checked to add information to the transcripts. To 
enhance trustworthiness and credibility of data analysis, 
a technique known as member checking was applied by 
returning each transcript to the respective participant to 
confirm the content of the interview.
Using the phenomenological approach, we high-
lighted and coded keywords which indicated key factors in 
prescribing statins from the transcripts. The same code was 
assigned to the same keyword. We categorised the codes in 
minor subthemes, subthemes and final major themes. The 
encoding process until obtaining subthemes was conducted 
independently by SP and RR. Disagreement regarding the 
codes and subthemes was discussed between SI and SP to 
reach a consensus. After subthemes were drawn, SP, SI and 
IWW discussed major themes and compared the themes 
with the findings from similar qualitative studies.
The final themes were refined by SI and KT and were 
mapped into a model that had previously been developed 
by Scoggins et al.42 This was a qualitative study, investigating 
factors influencing GPs to prescribe statins in England using 
in- depth interviews and focus group discussions. Interviews 
were done with senior managers primary care service organ-
isations (primary care trusts); focus group discussions were 
done with GPs of those organisations. The factors were clas-
sified into macrolevel, mesolevel and microlevel (figure 2).
Patient and public involvement
There was no patient and public involvement in the 
design, conduct or reporting of our research.
results
Ten physicians (nine females, one male) were willing to 
participate in this study. The mean age of all physicians was 
31.7 years old (ranged 24–56). Five physicians graduated 
between 2010 and 2015, four between 2000 and 2010, and 
one between 1980 and 1990. The mean duration of medical 
education was 6.6 years (ranged 5–12 years). All physicians 
were GPs. One was in the process of becoming a specialist 
in internal medicine. All physicians were working at more 
than one healthcare facility, four of them practised at three 
different healthcare facilities including at the secondary 
level. On average, the physicians examined around 99 
patients per week (range 30–250); the mean number of 
patients with CVD risk was 26.0 patients weekly (range 
5–100).
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Figure 2 Factors influencing general practitioners’ (GPs) 
prescribing. Factors found from our study that matched 
to factors found by Scoggins et al42 are presented in blue 
colour. BPJS, Badan Pengelola Jaminan Sosial; NICE, 
National Institute of Health and Clinical Excellence; PCT, 
primary care trust; reps, representatives.
Table 1 Themes, subthemes and codings of factors influencing statin prescribing
Major themes Subthemes Minor subthemes Specific keywords
Microlevel Patient’s characteristics Blood lipid levels Total cholesterol (varied among participants: from 200 
to 260 mg/dL), triglycerides, high LDL- c, low HDL- c, a 
combination of different lipid parameter
Symptoms Pain (varied in location: back of the neck, neck, 
shoulder), stiffness (neck, shoulder), warmth (neck), 
tingling (palms, feet), dizziness
Comorbidities Hypertension, diabetes, metabolic syndrome, heart 
disease
Contraindication Pregnancy, liver disease
Other risk factors Other risk factor without specifying the factor
Professional 
experience
Primary and secondary 
prevention of CVD
Prevention, CVD prevention
Macrolevel References Standard Standard
Guideline Guideline from ACC/AHA




e- Catalogue e- Catalogue
Referral system, referral 
back system
Patient referral
ACC, American College of Cardiology; AHA, American Heart Association; BPJS, Badan Pengelola Jaminan Sosial; CVD, cardiovascular 
disease; HDL- c, high- density lipoprotein cholesterol; LDL- c, low- density lipoprotein cholesterol.
Table 1 presents all major themes, subthemes and minor 
subthemes derived from transcript analysis. In general, 
there were two major themes drawn from the analysis: 
factors operating at (1) microlevel and (2) macrolevel. 
We did not identify any themes on the mesolevel. Figure 2 
shows the themes mapped into the model by Scoggins et 
al.42
theme 1: key factors in statin prescribing at the microlevel
The physicians described the key factor influencing their 
decision to prescribe statins as their inherent understanding 
of the characteristics of patients which indicate the patient’s 
need for a statin or a contraindication. There was some 
uncertainty around these characteristics which was insepa-
rable from other factors like motivation and education. See 
for further explanation below.
Subtheme: patient’s characteristics
Physicians described several patient’s characteristics 
which they considered to be important for prescribing 
statins. The most important characteristic was a high level 
of total cholesterol (TC); other characteristics were clin-
ical symptoms, comorbidities and other risk factors.
From the level of cholesterol of the patient him/
herself, if for example, it is more than 200 [mg/dL], 
for example 210, but it looks like it still can be [con-
trolled] with dietary pattern, I have not prescribed it 
yet. However, if, for example, there have been symp-
toms such as [on the] neck and maybe he/she has 
high blood pressure, usually a medication [is pre-
scribed]—simvastatin 1×10 mg. Actually, from my 
personal perspective, I do not look at the high blood 
pressure only. Only from the level of cholesterol, if, 
for example, it has been already high such as up to 
250, 260, I give [the medication] even though the 
blood pressure is not high. (Physician 1)
Interestingly, there is disagreement over the cut- off 
of the TC level to initiate statins. Other disagreements 
were also found on how these factors related to each 
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other when influencing the decision to prescribe statins. 
These variations of considerations were captured in the 
following quotes:
It depends on the patient whether there is a comor-
bidity or not. If there is a comorbidity, usually [with 
the level of cholesterol] above 200, [statin] has al-
ready been prescribed. If not, maybe above 240. If 
there is hypertension, diabetes, above 200 also [it 
will] be directly given. (Physician 8)
If, for example, the tryglycerides level is above 150, 
it can be prescribed. Then, after that… tryglycerides 
and total cholesterol. [For total cholesterol] usually 
above 200, it is prescribed. (Physician 10)
In prescribing statins, a physician also considered a situ-
ation where statin administration was contraindicated as 
quoted below:
First, there has to be a clear or an appropriate in-
dication. Then, whether there is a contraindication 
for the patient to use the medication for example in 
patients with liver disorder, then in patients who are 
pregnant—this is also a relative contraindication for 
statin administration. (Physician 6)
Subtheme: professional experience of the prescribing physicians
This subtheme focused more on the personal choice of 
physicians. A mindset of CV event prevention motivated 
physicians to prescribe statins as described below:
I give statins to the patient with high cholesterol lip-
id not just to decrease the level of the cholesterol. I 
mean that, you know that patient with high choles-
terol lipid has much more risk for cardiovascular in-
cident, because, in my knowledge, if the cholesterol 
level in the blood is so high, [it] can cause the plaque 
in the vascular, in the blood vessels. If the plaque be-
comes unstable, [it] can cause a rupture and make 
a mismatched perfusion and demand. So, I give the 
statin for the cholesterolemias, uh… the high cho-
lesterol level in the laboratory test, other reason—no 
other reason, I think. It’s the main reason. It’s my first 
reason to give [is] to prevent. It prevents the cardio, 
the risk of cardiovascular incident. (Physician 4)
… for statin administration as a medication to manage 
dyslipidemia, especially in patients with dyslipidemia 
or in patients with high risk of cardiovascular disease 
events that it can be as preventive therapy in cardio-
vascular disease, such as in patients who have already 
had a coronary heart disease or in patients with 
diabetes mellitus and… and with a risk, with periph-
eral artery disease so to say, hence there is a place to 
give [statin] or in patients with stroke. (Physician 6)
theme 2: key factors in statin prescribing operating at the 
macrolevel
We found that international information or references 
framed the physician’s mindset of patients who were 
candidates to receive statins. Furthermore, the NHIS 
supported or hindered the decision to prescribe statins.
Subtheme: references
References including journals and guidelines were infor-
mation sources which may frame physicians’ knowledge 
on which patients to prescribe statins for. These factors 
were not mentioned initially by participants but elicited 
through probing questions. The sources mentioned 
included therapeutic guidelines covered during medical 
education as well as local and global standards.
I do… as in the standard operating procedure, that 
is, giving a healthy lifestyle first… a healthy dietary 
lifestyle. The standard operating procedure is from 
sources for example from journals… yes…also with 
medical references in the past… got from the college 
and when I was in the hospital [during internship as 
a junior physician] (Physician 2)
In the past Framingham score was used to deter-
mine the risk for cardiovascular events. Now there is 
a new published guideline where [the risk] was not 
calculated from the Framingham score but [also] 
saw other risk factors. If not mistaken, [the guide-
line] was issued by American Heart Association also. 
(Physician 6)
There is a standard for that. If, for example, [the level 
of cholesterol] is above 250, the medication is just 
started. If it is between 200–250, counseling related 
to dietary pattern and lifestyle only. (Physician 9)
Subtheme: NHIS
Although the new NHIS means more patients get free 
access to medicines, there are still criteria to prescribe 
statins for reimbursement in the National Formulary which 
may or may not facilitate prescribing. For example, in the 
National Formulary, it was stated that pravastatin was to be 
given only to patients with hyperlipidaemia who had LDL- c 
level >160 mg/dL, to patients with coronary heart disease, 
and patients with diabetes and macroalbuminuria.29 30 This 
suggested that physicians would tend to prescribe to this 
type of patients or would prescribe it anyway if the patient 
did not meet this strict criteria but was considered to need 
a statin with the consequence it would not be reimbursed 
by BPJS.
The price is cheap, [it] is easy to obtain… in terms 
of it is available everywhere, then also available in ge-
neric. This also does not make it difficult for some 
patients even more when retired elderly patients do 
not have money but using BPJS. So, I think that is my 
consideration. (Physician 5)
BPJS will only reimburse the administration of statins 
for LDL above 160. Therefore, if it is under 160, 
patients usually buy it by themselves, so we prescribe. 
Meanwhile, specialists in hospitals usually prescribe 
but this is not reimbursed by BPJS… so we help by 
prescribe it again. (Physician 8)
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No, if indeed only the cholesterol is high, I think no 
need to refer [the patient]. No diabetes, nothing… 
we usually prescribe directly, unless when simvastatin 
is incidentally not available in Puskesmas… he/she 
[the patient] insists because he/she has a right… 
sometimes the medication is not available. He/she 
has the right… insurance right, for example he/
she wants a referral, we refer. However, there he/she 
also does not certainly obtain [a statin] if the LDL is 
under 160. (Physician 8)
A theme categorised under Pandora box
We attempted to elicit the impact of pharmaceutical 
companies and their marketing strategy related to statin 
prescribing, but physicians preferred to not discuss this 
topic with the researcher.
DIsCussIOn
Physicians’ decision to prescribe statins was influenced by 
factors operating at the microlevel and macrolevel which 
mapped well on the framework developed by Scoggins et al 
(2006) in a study on the factors influencing GPs prescribing 
of statins in primary care in England. The key microlevel 
factor was a set of patient’s characteristics, especially the 
high level of TC. At the macrolevel, physicians explained 
that their knowledge on prescribing was grounded in their 
education at university as well as reading guidelines or 
other reference sources such as medical journals. Another 
macrolevel factor was the new NHIS which facilitated or 
limited the prescribing of statins.
The strength of this study lies in the use of a qualita-
tive method to explore processes behind the behaviour 
of prescribing statins in Indonesia, an LMIC in transition 
to achieve UHC. The validity of the data was improved 
by follow- up interviews, member checking process, inde-
pendent coders and discussion with several researchers to 
reach consensus. Although we have reached code satura-
tion with our interviews, we only interviewed a relatively 
small number of physicians having relatively homogenous 
characteristics from one city in one province in Indonesia. 
Furthermore, the interviewer knew a number of the physi-
cians personally and this may have had an impact on the 
willingness to share sensitive information. The interviewer 
had the subjective impression that those interviews were 
longer and contained more information than the inter-
views with the physicians which she met the first time. 
Owton and Allen- Collinson discussed the use of friendship 
approach for data collection in ethnographic research. 
Although they noted interactional challenges during inter-
views, for example, emotional overload and power struggle, 
due to a role conflict being a friend and a researcher, but 
overall, this approach revealed more personal and sensitive 
information in some encounters.43 Nevertheless, several of 
our findings are comparable with other qualitative studies. 
Therefore, although the current study is explorative, our 
findings are the foundation for a future quantitative study, 
for example, surveys and interventions, in Indonesia. More 
qualitative work on eliciting factors influencing physician’s 
prescribing behaviour in other Asian regions and other 
therapeutic areas could complement our findings.
Similar to Scoggins et al (2006), our study found the 
clinical need of patients as an important factor to consider 
prescribing statins. However, physicians in our study 
described the clinical needs in more detail, mainly the level 
of TC and other risk factors potentially increasing the risk 
of CVD. Of note, the physicians did not specifically differ-
entiate between statin prescribed for primary or secondary 
prevention of CVD. Interestingly, the range of cholesterol 
levels to start statins ranged from 200 mg/dL to 260 mg/
dL and there was also a variation in taking other CVD risk 
factors into account. For example, one physician decided 
to give a statin when the TC level ≥210 mg/dL and the 
patient also had clinical symptoms and comorbidities while 
another physician only prescribed statins when the patient’s 
TC level was ≥260 mg/dL without the presence of comor-
bidities. This practice was not in line with the local guide-
line to initiate statin therapy.2 The patient’s total CV risk 
calculation was only acknowledged once after probing. This 
variation may lead to underprescribing or overprescribing 
of statins. The hesitation and inconsistency in using risk 
assessment tools as a guidance to initiate statin therapy have 
also been revealed in another qualitative study performed 
among GPs in the UK which showed that GPs found it diffi-
cult to interpret the tool for Asian patients and therefore 
preferred to assess the risk intuitively.44 The physicians in 
our study had some general background knowledge on 
statin prescribing which was by and large in line with the 
National Formulary. They did not mention the use of the 
national guideline issued by the IHA as sources to guide 
statin prescribing. This raises the question whether this 
guideline is sufficiently promoted.
Our general findings are also in agreement with a report 
from WHO on the drug use situation in Indonesia in 2011. 
It reported non- uniform sources of drug information used 
by physicians; they could be old text books from medical 
school or the internet with little use of up- to- date sources 
of independent drug information. The national standard 
treatment guideline for PHCs was not used much by physi-
cians.45 Even if it was used, there was no recommendation 
to use statins in patients with coronary heart disease as the 
guideline was developed when statins had not routinely 
been used in clinical practice.46
We could not disclose the role of medical represen-
tatives or pharmaceutical companies as shown in other 
studies24 42 in influencing statin prescribing. Most likely the 
interviewees perceived this topic as too controversial within 
both the medical profession and broader community to 
be willing to discuss it.47 Nevertheless, the WHO report 
suggested medical representatives from pharmaceutical 
companies as one of probable sources of drug information 
used by most physicians.45 As the WHO report is based on a 
situational analysis conducted in 2011 where the NHIS was 
still not integrated, it is not possible to know to what extent 
the role of pharmaceutical companies has changed. As this 
question clearly created an ethical dilemma, therefore, a 
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collaboration with the Ministry of Health and professional 
bodies and councils is needed to provide a less biased 
answer.
Patients’ demand or request for medicines is a factor 
influencing physicians’ prescribing behaviour according 
to Scoggins et al (2006). This factor was not mentioned 
in our interviews although there was an indication that 
patient’s insistence may influence the physician to meet 
the patient’s expectation, for example, in granting a 
referral. The lack of involvement of the patients’ voice 
in the physicians’ decision can be caused by differences 
in physician–patient communication style which may be 
rooted in cultural differences between Southeast Asians 
and Westerners.48 49 The majority of studies exploring 
factors influencing physicians’ prescribing behaviour 
come from Western countries where the physician–
patient communication style is often based on a partner-
ship style with the concept of equity.20 24 42 44 50 51 Southeast 
Asian physicians commonly tend to communicate in a 
paternalistic or one- way style, which gives the physician 
a more dominant role towards the patient. The culture 
of Southeast Asian physicians in keeping a social distance 
supports this communication style.48 49
We found that the NHIS had a considerable influence 
on physicians’ prescribing decisions, in particular on 
the choice of generics. This is in line with the concept 
from Scoggins et al (2006) that prescribing decisions 
are influenced by factors operating at national context 
or macrolevel. However, Scoggins et al (2006) only list 
national and international evidence based on authorita-
tive journals, national guidelines, national media and the 
development of new treatments as factors. This difference 
may be explained because of differences in organising 
healthcare and reimbursement of medication between 
Indonesian and England.
In contrast to Scoggins et al,42 we did not identify any 
factors at the mesolevel such as benchmarking between 
different primary care practices, collaborations between 
primary care and specialists and regional formularies. 
This is understandable as strengthening the primary 
care sector is a recently developed strategy with the 
new NHIS in Indonesia. Therefore, activities which are 
common practice in the English primary care system at 
the mesolevel have not been established in Indonesia 
yet. This finding is an opportunity for the government to 
work on the mesolevel to strengthen rational prescribing 
behaviour.
The findings from our study indicate that physicians 
have a lack of awareness of specific guideline recommen-
dations, especially on the use of LDL- c level and total CV 
risk calculation as decisive factors to prescribe statins. 
Improved access to statins facilitated by the government 
through the new NHIS seemed to be a good first step in 
fostering rational prescribing. A next step would be to 
include the recommendations from clinical guidelines 
issued by IHA into this system, especially through the 
National Formulary.
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